Tamsulosin Production Cost Reports

The report provides a detailed analysis essential for establishing a Tamsulosin production plant. It encompasses all critical aspects necessary for Tamsulosin production, including the cost of Tamsulosin production, Tamsulosin plant cost, Tamsulosin production costs, and the overall Tamsulosin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Tamsulosin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Tamsulosin is a medication used in the pharmaceutical industry for the treatment of benign prostatic hyperplasia (BPH), a condition characterised by an enlarged prostate that causes difficulty in urination. It acts as a selective alpha-1A and alpha-1B adrenergic receptor antagonist, relaxing the smooth muscle in the prostate and bladder neck to improve urine flow and reduce symptoms associated with prostatic hyperplasia. Additionally, tamsulosin is used to facilitate the passage of ureteral stones and to assist in acute urinary retention by promoting better bladder emptying.

The tamsulosin market is driven by the increasing prevalence of benign prostatic hyperplasia (BPH) among the ageing global male population, mainly in regions like North America, Europe, and emerging markets such as Asia-Pacific and Latin America. This demographic trend, combined with growing awareness of prostate health and improved healthcare access, fuels steady demand for tamsulosin as a preferred treatment.

The expanding availability of affordable generic versions enhances accessibility, especially in price-sensitive markets, which boosts its market growth. Additionally, the adoption of combination therapies and the drug’s favourable side effect profile encourages widespread physician preference and stable long-term use. Additionally, regional healthcare infrastructure advancements and increased screening also contribute significantly to market growth. However, product purity is critical, with pharmaceutical-grade tamsulosin required to exceed 99% purity, alongside specific particle size distribution and limits on residual solvents and heavy metals to meet USP, EP, or JP pharmacopoeia standards, which impacts industrial tamsulosin procurement.

Raw Material for Tamsulosin Production

According to the Tamsulosin production plant project report, the raw material for Tamsulosin production includes 4-methoxyphenylacetone.

Production Process of Tamsulosin

The extensive Tamsulosin production cost report consists of the following major industrial production process:

1. Production from 4-methoxyphenylacetone: The production process of tamsulosin involves a multi-step synthetic process starting from 4-methoxyphenylacetone. In the first step, this compound undergoes chlorosulfonation followed by reaction with ammonia to form 5-acetonyl-2-methoxybenzene sulfonamide, a sulfonamide intermediate. This intermediate is then hydrogenated in the presence of catalysts like PtO2 or Raney nickel with (R)-(+)-α-methylbenzylamine to produce a chiral amine key intermediate with high stereoselectivity. This intermediate is debenzylated through hydrogenation over a Pd/C catalyst to yield (R)-5-(2-aminopropyl)-2-methoxybenzene sulfonamide. Finally, this amine is refluxed with 1-(2-bromoethoxy)-2-ethoxybenzene in ethanol to produce tamsulosin.

Properties of Tamsulosin

Tamsulosin, mainly available in its hydrochloride salt form, is a white to almost white crystalline powder with the molecular formula C20H28N2O5S·HCl and a molecular weight of 445 g/mol. It has a melting point in the range of 228-230 degree Celsius with decomposition. The compound is slightly soluble in water and sparingly soluble in ethanol and methanol, while being practically insoluble in non-polar solvents like hexane and ether. Its pH in a 1% aqueous solution ranges between 4.8 and 5.3. The key ionizable groups exhibit pKa values of about 8.37 for the secondary amine and 10.23 for the sulfonamide group. These properties influence its absorption and bioavailability as an alpha-1 adrenergic receptor antagonist used primarily to treat benign prostatic hyperplasia by relaxing smooth muscle in the bladder neck and prostate.